A Study of Selpercatinib (LY3527723) in Participants With Advanced Solid Tumors Including RET Fusion-positive Solid Tumors, Medullary Thyroid Cancer and Other Tumors With RET Activation
← catalyst calendarSponsored by Eli Lilly and Company (industry) · LLY — their whole pipeline →.
Phase
Phase 2
Status
Active, not recruiting
Study type
Interventional
Design
Na · None · Treatment
Enrollment
77actual
Sites
13
Country
China
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2020-03-16 | actual | When the study began enrolling |
| Primary completion | 2021-03-25 | actual | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | Nov 2028 | estimated | The whole study's end, after follow-up |
| First posted | 2020-02-21 | actual | When this record first appeared on the registry |
| Results posted | 2022-06-02 | actual | When the sponsor posted results to the registry |
| Record updated | 2026-08-07 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Conditions
- Solid Tumor
- Medullary Thyroid Cancer
Intervention
- Drug: Selpercatinib — also filed as LY3527723, LOXO-292
Primary outcomes
what the primary-completion date above is the date OFPrimary Analysis Set: Overall Response Rate (ORR): Percentage of Participants With Complete Response (CR) or Partial Response (PR) as Assessed by Independent Review Committee (IRC)
measured Date of First Dose to Disease Progression or Death (up to 12 Months)
Enrolled Population: Overall Response Rate (ORR): Percentage of Participants With Complete Response (CR) or Partial Response (PR) as Assessed by IRC
measured Date of First Dose to Disease Progression or Death (Up to 12 months)
Posted documents
hosted by the registry — we link, never re-serveStudy Protocolposted 2021-02-01 · 6.8 MB · Prot_000.pdf
Statistical Analysis Planposted 2021-04-25 · 4.1 MB · SAP_001.pdf
Publications
- PMID 39759832 — linked by the registry
- PMID 37655205 — linked by the registry
- PMID 37315261 — linked by the registry
- PMID 36062046 — linked by the registry
- PMID 35923928 — linked by the registry
Linked on the registry record. A “linked by the registry” entry is NLM's own automated PubMed match, not a claim by the sponsor that the paper reports this study.
Permalink · LLY's whole pipeline · Catalyst calendar · Every registered study · What changed